Inaxaplin Shows Kidney Benefit In Additional Patient Groups As Vertex Completes Key Trial Enrollment

H.C. Wainwright maintained a Buy rating and $641 price target for Vertex (VRTX), citing positive AMPLIFIED Cohort 1 data. The stock trades at $523.42, with a consensus Buy rating and high target of $672. Vertex's market cap is $132.3 billion, and it has delivered a 33% return over the past year. Other analysts also reiterated positive ratings and targets, reflecting confidence in Vertex's pipeline.

Vertex Pharmaceuticals (VRTX) reported positive Phase 2b AMPLIFIED study results for inaxaplin in APOL1-mediated kidney disease (AMKD) patients. Inaxaplin reduced UACR by -42.7% in modest proteinuria patients and -17.3% in those with type 2 diabetes. The drug was safe and well-tolerated. Vertex completed enrollment in the Phase 2/3 AMPLITUDE trial, with interim analysis expected in early 2027, potentially supporting accelerated U.S. approval.

The XBI biotech ETF has surged 25% this year and 80% over 12 months, driven by big pharma acquisitions to offset patent expirations. Key deals include Vertex's $10B acquisition of Crinetics and Eli Lilly's $3.8B deal for AtaiBeckley. Potential targets include Viking Therapeutics and Sellas Life Sciences. Retail sentiment is extremely bearish, with XBI at a record-low score of 21.

Vertex Pharmaceuticals (VRTX) shares have risen 13% year-to-date but have pulled back 8% from their 52-week high. Q2 revenue grew 12% to $3.33B, with EPS up 8% to $4.31. The company raised full-year revenue guidance to $13.1B-$13.2B. Key catalysts include label expansion for Casgevy, potential approval for povetacicept, and Phase 2 trials for inaxaplin. Vertex's CF business remains strong with no significant competition.

Vertex Pharmaceuticals (VRTX) highlighted its pipeline advancements, including potential treatments for kidney diseases, pain management, and endocrine disorders. The company expects interim analysis for inaxaplin in Q1 2027 and a PDUFA date for povetacicept in IgAN by Nov. 30, 2026. Vertex also reported progress in its pain franchise, JOURNAVX, and the acquisition of Crinetics Pharmaceuticals, with peak sales potential of $5 billion for PALSONIFY and atumelnant.

Vertex Pharmaceuticals (VRTX) acquired Crinetics for $10B, gaining Palsonify, an approved acromegaly treatment, and atumelnant, a CAH drug in Phase 3. Citigroup expects Palsonify to generate $700M in annual sales by 2030, with atumelnant adding upside. The deal diversifies Vertex's revenue beyond cystic fibrosis but carries execution risks.